Esperion Therapeutics ESPR Accrued variable consideration
Accrued variable consideration at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:AccruedVariableConsiderationCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accrued variable consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accrued variable consideration?
- Esperion Therapeutics (ESPR) reported accrued variable consideration of $85.81M in Q1 2026.
- How has Esperion Therapeutics's accrued variable consideration changed year-over-year?
- Esperion Therapeutics's accrued variable consideration increased by 53.2% year-over-year, from $56.01M to $85.81M.
- What is the long-term trend for Esperion Therapeutics's accrued variable consideration?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accrued variable consideration has grown at a 77.4% compound annual growth rate (CAGR), from $5.03M to $88.2M.
- What does accrued variable consideration mean?
- This reflects estimated liabilities related to rebates, chargebacks, and other price concessions offered to customers or payers for product sales. It is a key indicator of net revenue realization and the impact of commercial contracting strategies. High accruals may signal aggressive sales growth or significant competitive pressure on pricing.